Abstract:Precision medicine relies on the idea that, for a particular targeted agent, only a subpopulation of patients is sensitive to it and thus may benefit from it therapeutically. In practice, it is often assumed based on preclinical data that a treatment-sensitive subpopulation is known, and moreover that the agent is substantively efficacious in that subpopulation. Due to important differences between preclinical settings and human biology, however, data from patients treated with a new targeted agent often show that one or both of these assumptions are false. This paper provides a Bayesian randomized group sequential enrichment design that compares an experimental treatment to a control based on survival time and uses early response as an ancillary outcome to assist with adaptive variable selection and enrichment. Initially, the design enrolls patients under broad eligibility criteria. At each interim decision, submodels for regression of response and survival time on a baseline covariate vector and treatment are fit; variable selection is used to identify a covariate subvector that characterizes treatment-sensitive patients and determines a personalized benefit index, and comparative superiority and futility decisions are made. Enrollment of each cohort is restricted to the most recent adaptively identified treatment-sensitive patients. Group sequential decision cutoffs are calibrated to control overall type I error and account for the adaptive enrollment restriction. The design provides a basis for precision medicine by identifying a treatment-sensitive subpopulation, if it exists, and determining whether the experimental treatment is superior to the control in that subpopulation. A simulation study shows that the proposed design reliably identifies a sensitive subpopulation, yields much higher generalized power compared to several existing enrichment designs and a conventional all-comers group sequential design, and is robust.

Sample Size Estimation Using a Partially Clustered Frailty Model for Biomarker‐Strategy Designs With Multiple Treatments

Sample size estimation for cancer randomized trials in the presence of heterogeneous populations

Optimal Biomarker-Guided Design for Targeted Therapy with Imperfectly Measured Biomarkers

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomarkers

Optimal Marker-Strategy Clinical Trial Design to Detect Predictive Markers for Targeted Therapy

Two-Stage Marker-Stratified Clinical Trial Design in the Presence of Biomarker Misclassification

Hierarchical Bayesian Clustering Design of Multiple Biomarker Subgroups (HCOMBS)

A Bayesian Phase II Proof-of-concept Design for Clinical Trials with Longitudinal Endpoints.

An adaptive enrichment design using Bayesian model averaging for selection and threshold-identification of tailoring variables

Bayesian Group Sequential Enrichment Designs Based on Adaptive Regression of Response and Survival Time on Baseline Biomarkers.

Phase I Trial Design for Drug Combinations with Bayesian Model Averaging.

A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes.

Efficient and flexible simulation-based sample size determination for clinical trials with multiple design parameters

Biomarker-Guided Adaptive Enrichment Design with Threshold Detection for Clinical Trials with Time-to-Event Outcome

Subgroup-Based Adaptive (SUBA) Designs for Multi-arm Biomarker Trials

Biomarker enrichment strategies: matching trial design to biomarker credentials

Randomized Phase II Cancer Clinical Trials to Validate Predictive Biomarkers

New designs for Bayesian adaptive cluster-randomized trials

Sample Size Estimation for Stratified Cluster Randomization Trial with Survival Endpoint.

Bayesian Solutions for Assessing Differential Effects in Biomarker Positive and Negative Subgroups